Sellar and perisellar meningiomas: effects on pituitary function in a Spanish cohort observational study
Por:
Guerrero-Pérez, F, Biagetti, B, Paja-Fano, M, Menéndez-Torre, EL, Rivero, G, Dios, E, Hanzu, FA, Rojas-Marcos, PM, Irigaray, A, Rodríguez, MDM, García-Centeno, R, Fernández, LG, Enseñat, J, Mora, M, Villar-Taibo, R, García, IMO, Araujo-Castro, M, Gándara, C, García, MDO, Tenorio-Jiménez, C, Novo-Rodriguez, C, Civantos, S, Simó-Servat, A, Aulinas, A, Asla, Q, Cordido, F, Novoa-Testa, I, Xifra, G, Ayala-Conte, M, Zamarron, A, Berrocal, MIG, Iglesias, P
Publicada:
1 feb 2025
Resumen:
PurposeStudies focused on the effects of sellar and/or perisellar (S/PS) meningiomas on pituitary function are scarce. The primary objective of the present study was to determinate the effects that S/PS meningiomas and their treatments have on pituitary function. Also, we described the clinical characteristics and therapeutic outcomes of the cohort of adult Spanish patients.MethodsA multicenter and retrospective study of patients with S/PS meningiomas attended in 20 tertiary Spanish centers.Results165 patients, 123 (74.5%) females, with median age of 61.4 [51-71] years were analyzed. At presentation, 115 (69.7%) had visual disturbance, 62 (37.6%) headache, 46 (27.9%) cranial nerve palsy and 34 (26.2%) hypopituitarism. Median tumor diameter was 29.1 [22-35.5] mm and cavernous sinus infiltration was detected in 95 (59%). As initial treatment, 128 (77.6%) underwent surgery, 25 (15.2%) received radiotherapy and 12 (7.3%) were clinically and radiologically monitored. Among operated patients, gross total resection (GTR) was achieved in 44 (34.4%), whereas in 84 (65.6%) the tumor was incompletely removed. Overall median follow-up was 5.7 [2.9-9.2] years. After treatments, hypopituitarism was present in 86 (53.4%) patients at the last evaluation, and it was associated with surgery extension (subtotal or GTR) but not with tumor subtype, type of radiotherapy or radiation dose received.ConclusionsS/PS meningiomas affect the pituitary function in 25% of the cases. However, after the implementation of treatments, hypopituitarism prevails in more than 50% of the cases. They are relatively large tumors and GTR is achieved in one third of the cases in whom hypopituitarism is more prevalent.
Filiaciones:
Guerrero-Pérez, F:
Hosp Univ Bellvitge, Dept Endocrinol & Nutr, Barcelona, Spain
Biomed Res Inst Bellvitge IDIBELL, Barcelona, Spain
Biagetti, B:
Hosp Univ Vall Hebron HUVH, Dept Endocrinol & Nutr, Barcelona, Spain
ENDO ERN, CIBERER U747 ISCIII, Madrid, Spain
Paja-Fano, M:
Hosp Univ Basurto, Dept Endocrinol & Nutr, Bilbao, Spain
Univ Basque Country UPV EHU, Bilbao, Spain
Menéndez-Torre, EL:
Hosp Univ Cent Asturias, Dept Endocrinol & Nutr, Oviedo, Spain
Inst Invest Biomed Principado Asturias ISPA, Grp ENDO, Oviedo, Spain
Univ Oviedo, Dept Med, Oviedo, Spain
Rivero, G:
Hosp Univ Puerta Hierro Majadahonda, Dept Endocrinol & Nutr, Madrid, Spain
Dios, E:
Univ Seville, Hosp Univ Virgen Rocio, Dept Endocrinol & Nutr, CSIC, Seville, Spain
Inst Biomed Sevilla IBiS, Unidad Gest Endocrinol & Nutr, Seville, Spain
Hanzu, FA:
Hosp Clin Barcelona, Dept Endocrinol & Nutr, Barcelona, Spain
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Univ Barcelona, Med Dept, Barcelona, Spain
Rojas-Marcos, PM:
Hosp Univ La Paz, Dept Endocrinol & Nutr, Madrid, Spain
Irigaray, A:
Hosp Univ Navarra, Dept Endocrinol & Nutr, Pamplona, Spain
Rodríguez, MDM:
Hosp Univ Cruces, Dept Endocrinol & Nutr, Bilbao, Spain
García-Centeno, R:
Hosp Univ Gregorio Maranon, Dept Endocrinol & Nutr, Madrid, Spain
Fernández, LG:
Hosp Univ Gregorio Maranon, Dept Endocrinol & Nutr, Madrid, Spain
Enseñat, J:
Univ Barcelona, Med Dept, Barcelona, Spain
Hosp Clin Barcelona, Dept Neurosurg, Barcelona, Spain
Mora, M:
Hosp Clin Barcelona, Dept Endocrinol & Nutr, Barcelona, Spain
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Univ Barcelona, Med Dept, Barcelona, Spain
Villar-Taibo, R:
Hosp Univ Santiago De Compostela, Immunol Serv, Santiago De Compostela, Spain
García, IMO:
Hosp Univ Virgen Nieves, Dept Neurosurg, Granada, Spain
Araujo-Castro, M:
Hosp Univ Ramon y Cajal, Dept Endocrinol & Nutr, Madrid, Spain
Inst Invest Biomed Ramon y Cajal IRYCIS, Madrid, Spain
Gándara, C:
Hosp Cabuenes, Dept Endocrinol & Nutr, Asturias, Spain
García, MDO:
Hosp Univ Navarra, Dept Endocrinol & Nutr, Pamplona, Spain
Tenorio-Jiménez, C:
Hosp Univ Virgen Nieves, Dept Endocrinol & Nutr, Granada, Spain
Novo-Rodriguez, C:
Hosp Univ Virgen Nieves, Dept Endocrinol & Nutr, Granada, Spain
Civantos, S:
Hosp Univ Fuenlabrada, Dept Endocrinol & Nutr, Madrid 28935, Spain
Simó-Servat, A:
Hosp Univ Mutua Terrassa, Dept Neurol, Barcelona, Spain
Aulinas, A:
ENDO ERN, CIBERER U747 ISCIII, Madrid, Spain
Hosp Santa Creu & Sant Pau, Dept Pathol, Barcelona, Spain
IR ST PAU, Barcelona, Spain
Asla, Q:
Hosp Santa Creu & Sant Pau, Dept Pathol, Barcelona, Spain
Cordido, F:
Hosp Univ Coruna, Dept Endocrinol & Nutr, La Coruna, Spain
Novoa-Testa, I:
Hosp Univ Coruna, Dept Endocrinol & Nutr, La Coruna, Spain
Xifra, G:
Hosp Univ Josep Trueta, Dept Endocrinol & Nutr, Girona, Spain
Ayala-Conte, M:
Hosp Univ Josep Trueta, Dept Endocrinol & Nutr, Girona, Spain
Zamarron, A:
Hosp Univ Puerta Hierro Majadahonda, Dept Neurosurg, Madrid, Spain
Berrocal, MIG:
Hosp Univ Puerta Hierro Majadahonda, Dept Radiat Oncol, Madrid, Spain
Iglesias, P:
Hosp Univ Puerta Hierro Majadahonda, Dept Endocrinol & Nutr, Madrid, Spain
Inst Invest Sanitaria Puerta Hierro Segovia Arana, Madrid, Spain
Green Submitted
|